Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

  title={Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?},
  author={George J Netto},
  journal={Nature Reviews Urology},
The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 61 extracted citations

Targeting Hsp90 in urothelial carcinoma

Oncotarget • 2015
View 4 Excerpts
Highly Influenced

Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications

International braz j urol : official journal of the Brazilian Society of Urology • 2018
View 12 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 145 references

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

Smith, C S.
Lancet Oncol • 2011

Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

Tickoo, K S.
BJU Int. 107, • 2011

Similar Papers

Loading similar papers…